20 % Discount on Therapeutic Classes - Combo Package Offer on the reports listed below. Offer available from 1 April 2014 to April 30, 2014.
Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A - The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.
Therapeutic Class Overview : Psoriasis – Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm - Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients.
Complete Report is Available @ http://www.reportsnreports.com/reports/275192-therapeutic-class-overview-psoriasis-plaque-psoriasis-psoriatic-arthritis-novel-oral-drugs-and-biologics-to-change-future-treatment-paradigm.html.
Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies - There are more than 1400 sustained or controlled release drugs approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of the overall international pharmaceutical market. Utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.
Complete Report is Available @ http://www.reportsnreports.com/reports/254091-innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies.html.
XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting?
Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry
In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide, Astellas/Medivation), Zytiga (Abiraterone acetate, JNJ), Jevtana (Cabazitaxel, Sanofi), & Xofigo (radium Ra 223, Boehringer Ingelheim) has evolved the treatment paradigm of treating late stage prostate cancer. In coming years, we expect this to repeat in early stage prostate cancer treatment (nmCRPC, before Prostectomy) due to launch of newer antiandrogens in this setting. Longer duration of therapy and high prevalence makes this earlier setting market more lucrative and bigger for newer options than late stage if they succeed.
Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon - With three products and eight players already in market – Japan biosimilar market will enter new phase of biosimilars with first ‘mab’ approval expected in 2014. This approval (Remicade- FY03/13A sales ¥73.5, infiximab from Nippon Kayaku by YE 14) will be marked as a milestone development because – 1.) it will open antibody biosimilar market in Japan, and 2.) the approval will be based largely from overseas data.
Complete Report is Available @ http://www.reportsnreports.com/reports/275199-therapeutic-class-overview-emergence-of-biogenerics-era-in-japan-its-time-to-welcome-antibody-biosimilars-of-foreign-origins-soon.html.
Therapeutic Class Overview : New Avatars Of Microbes Super Bugs A Growing Threat Worldwide - Novel approaches to treat infection is growing as the need is urgent! Misuse/overuse of antibiotics accelerated antimicrobial resistance (AMR) and has resulted in the emergence of “super bugs” which are posing life threatening challenges world wide. Many of the advances in medical treatment like cancer therapy; organ transplants etc. would go waste if the ability to fight infections during the treatment were not available. If that fails, the gains made in life-improving modern medical advantages will be lost creating a situation of - “one step forward two step back”. Novel approaches are immediately required to combat these “super infections” warranting need for new classes of antibiotics and other preventive/therapeutic approaches.
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on email@example.com and we would be happy to help you find the business intelligence that you need. Not limited to the Pharmaceuticals ReportsnReports.com offers research studies on agriculture, consumer goods, environment, advanced materials, public sector, food and beverages, energy and power, medical devices, healthcare, automotive, manufacturing & construction, semiconductor and electronics, IT & telecommunication, pharmaceuticals, retail, water, banking and financial services and much more.